Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol), glyburide (Diabeta), and glimepiride (Amaril), are preferred due to their enhanced potency and shorter duration of action.

The mechanism of sulfonylureas involves binding to ATP-sensitive potassium channels on pancreatic β cells. This interaction triggers cell membrane depolarization, leading to calcium influx and subsequent insulin release, effectively lowering blood glucose levels. Beyond stimulating insulin secretion, sulfonylureas reduce hepatic glucose production and augment peripheral glucose utilization, contributing to improved glycemic control. They are primarily prescribed when diet and exercise alone fail to manage type 2 diabetes and can be used solo or combined with other antidiabetic medications.

Despite their efficacy, sulfonylureas may cause adverse effects such as hypoglycemia, weight gain, and gastrointestinal disturbances. Hypoglycemia is the most common side effect, particularly in elderly patients or those with impaired kidney function. Careful dosage and monitoring are required to mitigate these risks. In conclusion, sulfonylureas are potent oral hypoglycemic agents that stimulate insulin release and improve insulin sensitivity, playing a critical role in managing type 2 diabetes. However, their use requires careful monitoring due to potential adverse effects.

Do Capítulo 25:

article

Now Playing

25.10 : Oral Hypoglycemic Agents: Sulfonylureas

Insulin and Hypoglycemic Drugs

86 Visualizações

article

25.1 : Homeostase da glicose: regulação da glicose no sangue

Insulin and Hypoglycemic Drugs

948 Visualizações

article

25.2 : Homeostase da glicose: ilhotas pancreáticas e secreção de insulina

Insulin and Hypoglycemic Drugs

709 Visualizações

article

25.3 : Insulina: o receptor e as vias de sinalização

Insulin and Hypoglycemic Drugs

763 Visualizações

article

25.4 : Fisiopatologia do Diabetes

Insulin and Hypoglycemic Drugs

557 Visualizações

article

25.5 : Diabetes: sintomas, diagnóstico e complicações

Insulin and Hypoglycemic Drugs

404 Visualizações

article

25.6 : Diabetes: Manejo e Farmacoterapia

Insulin and Hypoglycemic Drugs

159 Visualizações

article

25.7 : Insulina: Biossíntese, Química e Preparação

Insulin and Hypoglycemic Drugs

179 Visualizações

article

25.8 : Formulações de insulina: tipos e administração

Insulin and Hypoglycemic Drugs

90 Visualizações

article

25.9 : Insulina: Regime de dosagem e efeitos adversos

Insulin and Hypoglycemic Drugs

74 Visualizações

article

25.11 : Hipoglicemiantes orais: biguanidas e glitazonas

Insulin and Hypoglycemic Drugs

92 Visualizações

article

25.12 : Hipoglicemiantes orais: glinetos

Insulin and Hypoglycemic Drugs

70 Visualizações

article

25.13 : Agentes hipoglicemiantes orais: inibidores da α-glicosidase

Insulin and Hypoglycemic Drugs

69 Visualizações

article

25.14 : Agonistas do receptor semelhante ao glucagon

Insulin and Hypoglycemic Drugs

125 Visualizações

article

25.15 : Inibidores da dipeptidil peptidase 4

Insulin and Hypoglycemic Drugs

72 Visualizações

See More

JoVE Logo

Privacidade

Termos de uso

Políticas

Pesquisa

Educação

SOBRE A JoVE

Copyright © 2025 MyJoVE Corporation. Todos os direitos reservados